Phase I Clinical and Pharmacokinetic Study to Determine the Safety of Ecteinascidin-743 Administered as a Single Intravenous Infusion Over 60 Minutes Every 21 Days in Patients with Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2012
At a glance
- Drugs Trabectedin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jul 2012 New trial record